Abstract
The question of whether or not “genes” should be eligible for patent protection continues to be a cause of significant tension around the world in academic, policy and commercial contexts, as well as in the media and other public forums, for wide-ranging reasons. The primary focus of this paper is an analysis of a recent attempt in Australia to use legislative means to exclude from patent eligibility isolated nucleotide and polypeptide sequences that are similar to those that exist in nature.
Original language | English |
---|---|
Journal | 22(1) Journal of Law, Information and Science 32, 2012 |
Publication status | Published - 11 Oct 2014 |
Keywords
- Patents
- gene patents
- commercial
- research